Has Solly Chedid, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,717,785 in general payments to Solly Chedid, MD across 2,159 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Solly Chedid, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Solly Chedid, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Solly Chedid, MD

Hematology & Oncology · Pascagoula, MSNPI 1972586188

Payments from drug & device makers

$1,717,785in general payments, 2019–2025

Across 2,159 payments — averaging $795.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$436K
Merck$186K
E.r. Squibb & Sons, L.L.C.$184K
Ipsen Biopharmaceuticals, Inc$135K
Daiichi Sankyo Inc.$130K
Bristol Myers Squibb$104K
plus $543K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	410	$436,260
Merck	208	$185,525
E.r. Squibb & Sons, L.L.C.	231	$183,989
Ipsen Biopharmaceuticals, Inc	108	$134,663
Daiichi Sankyo Inc.	97	$130,011
Bristol Myers Squibb	108	$103,731
Sanofi	65	$60,702
AstraZeneca(2 entities)	84	$52,286
Seagen Inc.	83	$51,687
Pfizer	77	$51,232
GSK	43	$47,325
Boehringer Ingelheim	28	$36,151
Pharmaessentia USA Corporation	20	$29,161
Astellas Pharma US Inc	41	$28,567
Incyte Corporation	70	$27,917
Geron Corporation	20	$26,790
Amgen	53	$24,288
Epizyme, Inc.	26	$22,996
Johnson & Johnson(2 entities)	56	$16,877
Taiho Oncology, Inc.	18	$15,050
Exelixis Inc.	36	$9,258
Teva Pharmaceuticals USA, Inc.	11	$7,829
Puma Biotechnology, Inc.	14	$5,432
Genentech USA, Inc.	14	$5,315
Agios Pharmaceuticals, Inc.	18	$5,005
Janssen Scientific Affairs, LLC	4	$3,611
Pharmacosmos Therapeutics Inc.	17	$3,118
Astellas Pharma Global Development	1	$2,400
Beigene USA, Inc.	4	$2,007
Gilead(2 entities)	2	$1,635
Blueprint Medicines Corporation	1	$1,512
Morphosys, US Inc.	8	$1,293
Novartis	30	$602
Eisai Inc.	18	$364
Bayer	14	$315
Cardinal Health 110 LLC	1	$300
Takeda Pharmaceuticals U.S.A., Inc.	11	$265
Lilly USA, LLC	13	$251
AbbVie	10	$245
Pharmacyclics LLC, An Abbvie Company	8	$162
Rigel Pharmaceuticals, Inc.	8	$151
Foundation Medicine, Inc.	5	$132
Genmab U.S., Inc.	7	$130
Adaptive Biotechnologies Corporation	5	$128
Sanofi-aventis U.S. LLC	1	$100
Karyopharm Therapeutics Inc.	3	$81
AVEO Pharmaceuticals, Inc.	3	$60
Azurity Pharmaceuticals, Inc.	3	$52
EMD Serono, Inc.	3	$50
Amneal Pharmaceuticals LLC	3	$50
Sobi, Inc	2	$47
Tersera Therapeutics LLC	2	$46
Alnylam Pharmaceuticals Inc.	2	$42
Dendreon Pharmaceuticals LLC	2	$41
Tesaro, Inc.	2	$40
Jazz Pharmaceuticals Inc.	3	$40
Beone Medicines USA, Inc.	2	$36
Stemline Therapeutics Inc.	2	$35
Deciphera Pharmaceuticals Inc.	1	$25
G1 Therapeutics, Inc.	1	$24

How this compares

$1,717,785 in reported general payments places this provider in the 95th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$132,572

Medicare patients

207

Services billed

1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pascagoula

Daniel PattersonPascagoula$36K
Cory CarterPascagoula$3K
John HromHattiesburg$10M
Justin BakerJackson$2.1M
John HeneganJackson$1.2M
Carter MilnerJackson$261K
Andrew KellumTupelo$171K
Barbara CraftJackson$135K
Dennis MorganOxford$80K
Guangzhi QuJackson$78K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →